Search results
Results from the WOW.Com Content Network
The current version of the test is the Addenbrooke's Cognitive Examination-III (ACE-III). This consists of 19 activities which test five cognitive domains: attention, memory, fluency, language and visuospatial processing.
The MMSE may help differentiate different types of dementias. People with Alzheimer's disease may score significantly lower on orientation to time and place as well as recall, compared to those who have dementia with Lewy bodies, vascular dementia, or Parkinson's disease dementia. [25] [26] [27]
A new test may help predict who is at risk for Alzheimer's disease. ABC explains, "It measures a patient's risk of mental impairment based on several factors, including how quickly the patient can ...
Similar to the NINCDS-ADRDA Alzheimer's Criteria are the DSM-IV-TR criteria published by the American Psychiatric Association. [3] At the same time the advances in functional neuroimaging techniques such as PET or SPECT that have already proven their utility to differentiate Alzheimer's disease from other possible causes, [4] have led to proposals of revision of the NINCDS-ADRDA criteria that ...
Alzheimer's myths and facts debunked by WebMD and the Alzheimer's Association.
Scientists have identified a biomarker for Alzheimer's that may help doctors spot the early signs of protein buildup in the brain before it causes significant damage. New test may detect Alzheimer ...
The Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) is a brief neuropsychological assessment used to assess the severity of cognitive symptoms of dementia. It is one of the most widely used cognitive scales in clinical trials [ 1 ] and is considered to be the “gold standard” for assessing antidementia treatments.
Researchers from Lund University have found that a new blood test called PrecivityAD2 is about 90% accurate in identifying Alzheimer’s disease in people experiencing cognitive symptoms.